Answers are grounded in this paper and cite their sources.
This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.
No takes yet. Share an insight, caveat, or question.
Stern et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: